Summary of Study ST003481
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002138. The data can be accessed directly via it's Project DOI: 10.21228/M8882W This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003481 |
| Study Title | Therapeutic potential of galactooligosachaccharides and Lactobacillus reuteri supplementation on dextran sulfate sodium-induced gut inflammation |
| Study Summary | Dextran sulfate sodium (DSS)-induced inflammatory bowel disease characterized by intestinal inflammation, barrier dysfunction, and dysbiosis, with limited treatment options available. This study systematically investigates the therapeutic potential of a synbiotic composed of galactooligosaccharides (GOS) and Limosilactobacillus reuteri in a murine model of colitis, revealing that GOS and L. reuteri synergistically protect against intestinal inflammation and barrier dysfunction by promoting the synthesis of pentadecanoic acid, an odd-chain fatty acid, from Bacteroides acidifaciens (B. acidifaciens). Intestinal segments and feces from DSS-treated mice were collected for cytokines detection and metabolomics. Notably, the synbiotic, B. acidifaciens, and pentadecanoic acid are each capable of suppressing intestinal inflammation and enhancing tight junction by inhibiting NF-κB activation. Furthermore, similar reduction in B. acidifaciens and pentadecanoic acid levels are also observed in the feces from both human ulcerative colitis (UC) patients and lipopolysaccharide-induced intestinal inflammation in pigs. Our findings elucidate the protective mechanism of the synbiotic and highlight its therapeutic potential, along with B. acidifaciens and pentadecanoic acid, for intestinal inflammatory disorders. |
| Institute | China Agricultural University |
| Last Name | Wu |
| First Name | Yujun |
| Address | Yumingyuan West Road |
| yujun@cau.edu.cn | |
| Phone | 18801068572 |
| Submit Date | 2024-09-02 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | cdf |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-10-03 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN005716 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Waters Acquity |
| Column | Waters Acquity UPLC BEH C18 (100 x 2.1mm, 1.7um); Waters Acquity UPLC BEH C18 Vanguard pre-column (5 x 2.1mm, 1.7um) |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | Waters Xevo-TQ-S |
| Ion Mode | NEGATIVE |
| Units | nmol/g feces |
Chromatography:
| Chromatography ID: | CH004337 |
| Chromatography Summary: | ACQUITY UPLC BEH C18 1.7 µM VanGuard pre-column (2.1×5 mm) and ACQUITY UPLC BEH C18 1.7 µM analytical column (2.1 × 100 mm) |
| Instrument Name: | Waters Acquity |
| Column Name: | Waters Acquity UPLC BEH C18 (100 x 2.1mm, 1.7um); Waters Acquity UPLC BEH C18 Vanguard pre-column (5 x 2.1mm, 1.7um) |
| Column Temperature: | 40 |
| Flow Gradient: | 0-1 min (5% B), 1-11min (5-78% B), 11-13.5 min (78-95% B), 13.5-14 min (95-100% B), 14-16 min (100% B)， 16-16.1 min (100-5% B)， 16.1-18 min (5% B) |
| Flow Rate: | 0.40 mL/min |
| Solvent A: | 100% water; 0.1% formic acid |
| Solvent B: | 70% acetonitrile/30% Isopropanol |
| Chromatography Type: | Reversed phase |
